Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct 1;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

PMID:
23999433
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.

PMID:
23887971
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW.

Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5.

PMID:
23223358
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G.

Blood. 2013 Jan 3;121(1):159-69. doi: 10.1182/blood-2012-05-428573. Epub 2012 Oct 25.

PMID:
23100311
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

O'Hare T, Zabriskie MS, Eiring AM, Deininger MW.

Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317. Review. Erratum in: Nat Rev Cancer. 2012 Dec;12(12):886.

PMID:
22825216
[PubMed - indexed for MEDLINE]
6.

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW.

Leukemia. 2012 May;26(5):1140-3. doi: 10.1038/leu.2011.325. Epub 2011 Nov 18. No abstract available.

PMID:
22094585
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Advances in the treatment of chronic myeloid leukemia.

Eiring AM, Khorashad JS, Morley K, Deininger MW.

BMC Med. 2011 Aug 26;9:99. doi: 10.1186/1741-7015-9-99. Review.

PMID:
21867560
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The new role of microRNAs in cancer.

Perrotti D, Eiring AM.

Future Oncol. 2010 Aug;6(8):1203-6. doi: 10.2217/fon.10.78. No abstract available.

PMID:
20799864
[PubMed - indexed for MEDLINE]
Free Article
9.

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G.

Cancer Cell. 2010 Apr 13;17(4):333-47. doi: 10.1016/j.ccr.2010.03.008.

PMID:
20385359
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D.

Cell. 2010 Mar 5;140(5):652-65. doi: 10.1016/j.cell.2010.01.007.

PMID:
20211135
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.

Lunsford KE, Jayanshankar K, Eiring AM, Horne PH, Koester MA, Gao D, Bumgardner GL.

Am J Transplant. 2008 Jun;8(6):1113-28. doi: 10.1111/j.1600-6143.2008.02219.x.

PMID:
18522544
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.

Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D.

Blood. 2008 Jan 15;111(2):816-28. Epub 2007 Oct 9.

PMID:
17925491
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D.

J Clin Invest. 2007 Sep;117(9):2408-21.

PMID:
17717597
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D.

Blood. 2007 Aug 1;110(3):994-1003. Epub 2007 May 2.

PMID:
17475908
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Activation and maturation of alloreactive CD4-independent, CD8 cytolytic T cells.

Lunsford KE, Horne PH, Koester MA, Eiring AM, Walker JP, Dziema HL, Bumgardner GL.

Am J Transplant. 2006 Oct;6(10):2268-81. Epub 2006 Aug 4.

PMID:
16889609
[PubMed - indexed for MEDLINE]
Free Article
16.

Targeting LFA-1 and cd154 suppresses the in vivo activation and development of cytolytic (cd4-Independent) CD8+ T cells.

Lunsford KE, Koester MA, Eiring AM, Horne PH, Gao D, Bumgardner GL.

J Immunol. 2005 Dec 15;175(12):7855-66.

PMID:
16339521
[PubMed - indexed for MEDLINE]
Free Article
17.

CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody.

Horne PH, Lunsford KE, Eiring AM, Wang Y, Gao D, Bumgardner GL.

Transplantation. 2005 Aug 27;80(4):514-21.

PMID:
16123727
[PubMed - indexed for MEDLINE]
18.

Evidence for tissue-directed immune responses: analysis of CD4- and CD8-dependent alloimmunity.

Lunsford KE, Gao D, Eiring AM, Wang Y, Frankel WL, Bumgardner GL.

Transplantation. 2004 Oct 27;78(8):1125-33.

PMID:
15502708
[PubMed - indexed for MEDLINE]
19.

Critical role for CD8 T cells in allograft acceptance induced by DST and CD40/CD154 costimulatory blockade.

Gao D, Lunsford KE, Eiring AM, Bumgardner GL.

Am J Transplant. 2004 Jul;4(7):1061-70.

PMID:
15196062
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk